Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 PET Study in Healthy Men
NCT02093169Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Feb 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lu af35700 in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoints: Relationship between plasma concentrations and pharmacodynamic (PD) measures specified as binding potential, Relationship between plasma concentrations and PD measures specified as plasma concentrations of Lu AF35700, Lu AF36152 and Lu AF35700 + Lu AF36152 and 1 more. Started Feb 2014; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02093169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093169.